Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
← catalyst calendarSponsored by Tango Therapeutics, Inc. (industry) · TNGX — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
110actual
Sites
20
Countries
France, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision - Business Decisions
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-23 | actual | When the study began enrolling |
| Primary completion | 2025-12-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-30 | actual | The whole study's end, after follow-up |
| First posted | 2022-03-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Locally Advanced Solid Tumor
Intervention
- Drug: TNG908
Primary outcomes
what the primary-completion date above is the date OFPhase 1:
measured 28 days
Phase 2:
measured 16 weeks
Publications
- PMID 39756156 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · TNGX's whole pipeline · Catalyst calendar · Every registered study · What changed